- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Variation in the UCP2 and UCP3genes associates with abdominal obesity and serum lipids: The Finnish Diabetes Prevention Study
© Salopuro et al; licensee BioMed Central Ltd. 2009
Received: 25 March 2009
Accepted: 21 September 2009
Published: 21 September 2009
We explored the associations of three variants in the uncoupling protein 2 (UCP2) gene, one variant in the UCP2-UCP3 intergenic region and five variants in the uncoupling protein 3 (UCP3) gene with obesity and diabetes related traits in subjects with impaired glucose tolerance participating in Finnish Diabetes Prevention Study. Altogether 507 overweight individuals (body mass index: 31.2 ± 4.5 kg/m2, age: 55 ± 7 years) for whom DNA was available were randomized to either an intensified diet and physical activity group or to a conventional care control group.
We analysed the data from the baseline and annual follow-up visits from years 1, 2 and 3. Measurements of anthropometry, plasma glucose and serum insulin in oral glucose tolerance test, serum total cholesterol, HDL-cholesterol and triglycerides were included. The median follow-up time for type 2 diabetes incidence was 7 years. Genetic variants were screened by restriction fragment length polymorphism or Illumina method.
UCP3 gene variant rs3781907 was associated with increased serum total and LDL-cholesterol levels, at baseline and during the follow-up period. The same variant was associated with a higher risk of type 2 diabetes. Variants rs1726745, rs11235972 and rs1800849 in the UCP3 gene associated with serum total and LDL-cholesterol at baseline. Haploblock including variants rs659366, rs653529, rs15763, and rs1726745 was associated with measures of abdominal obesity at baseline and in the longitudinal analysis. The haplotype comprising alleles rs659366-G, rs653529-A, rs15763-G and rs1726745-A was associated with higher waist-to-hip ratio, and haplotype comprising alleles rs3781907-G, rs11235972-A, and rs1800849-T was associated with increased serum total and LDL-cholesterol concentrations.
Genetic variation in the UCP2-UCP3 gene cluster may act as a modifier increasing serum lipid levels and indices of abdominal obesity, and may thereby also contribute to the metabolic aberrations observed in obesity and type 2 diabetes.
UCP2 is a member of the mitochondrial inner membrane carrier family that is expressed in a wide variety of tissues, for example in adipose tissue, skeletal muscle and pancreatic islets. The function of UCP2 is tissue-dependent, and its potential roles include the regulation of fat metabolism directly and indirectly, e.g. via effects on insulin secretion . It also has a role in the limitation of reactive oxygen species (ROS) and macrophage-mediated immunity . Recent studies have established UCP2 as a key component of beta cell glucose sensing, since it seems to regulate glucose-stimulated insulin secretion [1, 3], and is also a critical link between obesity, beta cell dysfunction and type 2 diabetes (T2DM) . UCP2 and UCP3 genes are located on chromosome 11q13 adjacent to one another [5, 6]. In a recent meta-analysis of genome-wide linkage studies, suggestive evidence for chromosome 11q13.3-22.3 was observed for body mass index (BMI) -defined obesity .
There are three common variants in the UCP2 gene, one located in the promoter region (-866 GA, rs659366), one is a missense variant in exon 4 (Ala55Val, CT, rs660339), and one locates in the untranslated exon 8 (45 bp DelIns in the 3'UTR). Their association with traits related to obesity, energy expenditure or T2DM remains controversial due to inconsistent findings [8–19]. Studies on rs659366 have demonstrated associations between the A allele and enhanced adipose tissue mRNA expression and decreased risk of obesity , increased energy expenditure , reduced beta cell function and higher risk of T2DM , lower insulin secretion , decreased lipid oxidation , increased preclinical atherosclerosis in women , and increased coronary heart disease risk . Krempler et al.  have shown that the functional rs659366 variant, located in a multifunctional cis-regulatory site, acts as a binding site for a pancreatic transcription factor PAX6. Wang et al.  found that the heterozygous combination of the three variants (-866 GA, Val55Val, DelIns) was associated with increased BMI, triglyceride and fasting insulin levels.
While the UCP2 gene is expressed in almost all tissues, expression of the UCP3 gene is mostly restricted to skeletal muscle and brown adipose tissue. Suggested functions of UCP3 include regulation of fatty acid metabolism, redox state, and ROS formation [22, 23]. UCP3 seems to be involved in the protection of mitochondria against lipotoxicity . The human UCP3 gene gives rise to two main alternative transcripts, the shorter one having a polyadenylation site in intron 6, which terminates approximately 50% of the transcripts. Therefore, human UCP3 exists as long (UCP3L) and short (UCP3S) forms . A promoter region variant -55 CT (rs1800849) is potentially interesting since it is located only 6 bp apart from the TATA box and 4 bp from a DR1 site, which is a part of a retinoic acid response element . In Pima Indians the rs1800849-T allele increased UCP3 mRNA expression in skeletal muscle compared with the C allele , and the expression level correlated negatively with BMI . A direct correlation between sleeping metabolic rate and 24 h energy expenditure and the expression of UCP3 mRNA was also found in Pima Indians . Moreover, the rs1800849-T allele was associated with higher waist-to-hip ratio (WHR) , decreased risk of T2DM, and atherogenic lipid profile , but associations with BMI were controversial [29–32]. No association between rs1800849 and body weight was seen in several studies [25, 33–36].
The aim of this study was to assess the impact of five previously unexplored variants in addition to the four above-mentioned known genetic variants in the UCP2-UCP3 gene cluster, either individually or as haplotypes, on obesity and T2DM related traits. The study subjects with impaired glucose tolerance (IGT) were prospectively followed in the Finnish Diabetes Prevention Study (DPS) [37, 38].
Subjects and research design
The DPS is a randomised, controlled, multicenter study carried out in Finland in 1993-2000. The DPS study design and methods used have been reported in detail elsewhere [37–39]. The main inclusion criteria were BMI over 25 kg/m2, age 40 to 64 years, IGT based on the mean values of two oral glucose tolerance tests (OGTTs). A total of 522 individuals with IGT were randomised into either a control group or an intensive, individualised diet and physical exercise intervention group stratified according to the clinic, sex, and the mean plasma glucose concentration two hours after an oral glucose load (7.8 to 9.4 or 9.5 to 11.0 mmol/l). DNA was available from 507 individuals (166 men and 341 women). Their mean BMI was 31.2 ± 4.5 kg/m2 and age 55.3 ± 7.1 years. At the baseline, 5% of the individuals were using cholesterol lowering medication. The study protocol was approved by the Ethics Committee of the National Public Health Institute in Helsinki, Finland, and the study participants gave written informed consent. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research.
A medical history was taken and a physical examination done at baseline and at each annual follow-up visit . In this study, measurements from baseline to the 3-year examination were used, including height, weight, waist circumference (WC), hip circumference, serum lipid levels, and 2 h OGTT with glucose and insulin levels before (0 min) and after a 75 g glucose load (120 min) . Plasma glucose was measured at each centre by standard methods. The serum insulin concentration was measured in a central laboratory by a radioimmunoassay method (Pharmacia, Uppsala, Sweden). The intra-assay coefficient of variation was 5.3% and the interassay coefficient of variation was 7.6%. Homeostasis model for insulin resistance (HOMA-IR) was calculated using the formula: fasting plasma glucose (mmol/l) × fasting serum insulin (mU/l)/22.5, and homeostasis model for insulin secretion (HOMA-IS) was calculated as 20 × fasting serum insulin (mU/l)/(fasting plasma glucose [mmol/l] - 3.5) . Serum levels of total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were measured by enzymatic assay in the central laboratory in Helsinki. Formula of Friedewald  was used to calculate the concentration of low density lipoprotein (LDL) cholesterol.
The single nucleotide polymorphisms (SNP) for genotype analysis were selected from the region spanning the UCP2 and UCP3 genes (~34.4 kb) by using the International HapMap database and Tagger software http://www.broad.mit.edu/mpg/tagger/server.html. Rs660339, rs659366, and rs1800849 were forced in the selection procedure. The SNPs covered 86.2% of the genetic information of the studied region (r2>0.8). It should be noted that the DelIns variant of the UCP2 gene is not included in the database, since it is not a SNP but a 45 bp insertion.
The rs659366 and rs660339 variants of the UCP2 gene and the rs1800849 variant of the UCP3 gene were screened by the restriction fragment length polymorphism after digestion with MluI, HincII and HaeIII, respectively, with minor modifications to previously described methods [9, 15, 43]. The DelIns variant of the UCP2 gene was analysed by gel electrophoresis of the PCR-product. The intergenic region variant rs653529 and four variants locating in the UCP3 gene (rs15763, rs1726745, rs3781907, rs11235972) were genotyped by using the custom Golden Gate genotyping reagents and consumables (Illumina Inc, San Diego, CA). Only 501 (rs1726745) or 502 (rs653529, rs15763, rs3781907, rs11235972) subjects were successfully genotyped by Illumina. For other variants, n = 507.
The data were analysed using the SPSS/WIN program version 14.0 (SPSS, Chigago, IL, USA). The normality of distributions of study variables was evaluated with the Kolmogorov-Smirnov test with Lilliefors' correction, and appropriate transformation was used when necessary. For variables with skewed distribution, Kruskal-Wallis test was used. Univariate analysis of variance was used to compare the effect of the gene variants on continuous variables. Adjustment for age, gender and BMI was done, when appropriate. In addition, serum lipoprotein and lipid concentrations were adjusted for the use of cholesterol-lowering medication as well. Chi square test was used in comparison of categorical variables. The relative changes in HOMA-IS from baseline to three years were calculated as follows: [(parameter 3-year - parameterbaseline)/parameterbaseline] × 100%. Longitudinal changes were examined using repeated measures of General Linear Model. Homogeneity of variances was tested using Levene's test. Cox regression analysis, adjusted for the study group, baseline weight, weight change and baseline fasting plasma glucose, was performed to evaluate whether the gene variants predicted the development of T2DM.
Linkage disequilibrium (LD) statistics were calculated by Haploview software  and haplotype analysis was done by THESIAS 3.1 http://ecgene.net/genecanvas, which is based on the stochastic-EM algorithm. Haplotype analyses of the quantitative variables were adjusted for age, gender and BMI, when appropriate. The survival analysis for haplotypes was adjusted for the study group, baseline weight, weight change and baseline fasting plasma glucose.
A p-value < 0.05 was considered statistically significant. Correction for multiple hypothesis testing was performed with false discovery rate (FDR) using Q-value 1.0 software. π0 was estimated with bootstrap method  using λ range from 0 to 0.9 by 0.05. Due to the distribution of p-values, the λ was set to 0 for correcting the results of Cox regression. Essentially, this is a conservative way of calculating FDR and thereby produces the estimate implicit in the Benjamini and Hochberg methodology. In text, q stands for FDR, and is reported for each p < 0.05 and should be interpreted as minimum FDR that is incurred when calling that test significant. Data are given as means ± SD, unless otherwise indicated.
Genotype and allele frequencies and LD
Pairwise linkage disequilibrium, presented as D' and r2 values, among the nine variants in UCP2 and UCP3 genes (haploblocks are shown bolded)
rs660339 CT (0.470)
rs659366 GA (0.403)
rs653529 AG (0.415)
rs15763 GA (0.218)
rs1726745 GA (0.403)
rs3781907 AG (0.327)
rs11235972 GA (0.371)
rs1800849 CT (0.377)
Baseline characteristics of subjects
No significant differences were observed among the genotypes regarding body weight, BMI, fasting and 2-h insulin levels, HOMA-IR or HOMA-IS. Fasting and 2-h glucose levels differed among the rs660339 genotypes (p/q 0.006/0.006 and 0.025/0.010, respectively), and among the rs659366 genotypes (p/q 0.007/0.006 and 0.025/0.010, respectively). Specifically, the rs660339-CC and rs659366-AA homozygotes had the highest fasting glucose concentrations and the rs660339-CC and rs659366-GG homozygotes had the highest 2-h glucose concentrations. In addition, rs653529 associated with 2-h glucose level, so that the individuals with AA-genotype had the highest values (p/q 0.028/0.010), but the associations with glucose were not dependent on the allele dosage.
Associations of representative SNPs in the UCP2-UCP3 gene region with indices of abdominal obesity at the baseline
Homozygous for the common allele
Homozygous for the rare allele
102 ± 11
101 ± 11
100 ± 11
0.93 ± 0.07
0.92 ± 0.07
0.91 ± 0.08
0.61 ± 0.06
0.61 ± 0.06
0.61 ± 0.07
102 ± 11
101 ± 11
100 ± 11
0.93 ± 0.07
0.92 ± 0.07
0.91 ± 0.08
0.61 ± 0.06
0.61 ± 0.06
0.60 ± 0.07
102 ± 11
100 ± 10
100 ± 12
0.92 ± 0.07
0.92 ± 0.07
0.90 ± 0.07
0.61 ± 0.07
0.60 ± 0.06
0.60 ± 0.07
100 ± 11
102 ± 11
102 ± 11
0.91 ± 0.08
0.92 ± 0.07
0.93 ± 0.07
0.60 ± 0.06
0.62 ± 0.06
0.61 ± 0.07
Baseline characteristics and conversion to type 2 diabetes (T2DM) according to the genotypes of SNP rs3781907 at UCP3 gene
56 ± 7
55 ± 7
53 ± 7
86.3 ± 14.6
85.8 ± 13.5
87.3 ± 15.9
31.3 ± 4.8
31.1 ± 4.2
31.6 ± 5.2
0.92 ± 0.07
0.92 ± 0.07
0.93 ± 0.08
Fasting plasma glucose (mmol/l)
6.2 ± 0.8
6.1 ± 0.7
6.2 ± 0.7
Fasting serum insulin (pmol/l)
85 ± 40
92 ± 51
86 ± 30
Serum total cholesterol (mmol/l)
5.5 ± 0.9
5.7 ± 0.9
5.9 ± 1.0
Serum LDL-cholesterol (mmol/l)
3.5 ± 0.8
3.7 ± 0.8
3.9 ± 1.0
Serum HDL-cholesterol (mmol/l)
1.22 ± 0.29
1.22 ± 0.30
1.17 ± 0.25
Serum triglycerides (mmol/l)
1.69 ± 0.73
1.74 ± 0.83
1.81 ± 0.70
Total cholesterol-to-HDL-cholesterol ratio
4.73 ± 1.22
4.90 ± 1.26
5.15 ± 1.15
Converters to T2DM (n/%)a
The 3-year changes
The 3-year change in HOMA-IS was associated similarly with all three UCP2 variants (DelIns, rs660339, rs659366), the intergenic region variant rs653529 and UCP3 variant rs15763, showing increased values for wild-type subjects, intermediate for heterozygous and the lowest values for homozygous subjects (p/q 0.004/0.304, 0.016/0.325, 0.037/0.325, 0.018/0.325 and 0.016/0.325, respectively), whereas no association with other four UCP3 variants was found.
Frequencies and associations of the major haplotypes (frequency ≥ 0.05) of three haploblocks in the UCP2-UCP3 gene region
↓ WHR, p = 0.050b
↑ cholesterol, p = 0.006c
↑ LDL, p = 0.024c
↓ΔLDL, p = 0.037c
In block 2 the haplotype AGAG showed lower WHR at baseline when compared with the reference haplotype GAGA (p = 0.050). In block 3 the haplotype GAT had higher serum total cholesterol (p = 0.006) and LDL-cholesterol (p = 0.024) at baseline when compared with the reference haplotype AGC. Moreover, the haplotype AAT showed a greater decrease (0-3 years) in LDL-cholesterol level compared with the reference haplotype AGC during the 3-year follow-up (p = 0.037). No associations were seen for the haplotypes in the haploblock 1.
Conversion to T2DM
During a median follow-up of seven years 185 individuals (75 in the intervention group and 110 in the control group) developed T2DM. The subjects with the rs3781907-G allele were at a higher risk for T2DM when compared with subjects with AA genotype, with hazard ratio (HR) of 1.48 (95%CI 1.09-2.00), p/q 0.011/0.100. We also analysed the genotype × study group interaction for the diabetes conversion, but it was not statistically significant (p = 0.447). The percentage of subjects with AA genotype converting to T2DM was 33%, whereas it was 38% and 48% for the subjects with AG and GG genotypes, respectively (p/q 0.039/0.394) (Table 3). The percentages of converters were similar for both study groups, with GG genotype showing the highest and AA genotype showing the lowest percentages of converters.
Surprisingly, subjects in the intervention group carrying the UCP2 InsIns genotype were at a higher risk compared with subjects with Del allele, with HR 2.53 (95%CI 1.11-5.73), p/q 0.027/0.243. Such a risk increment was not seen in the control group, nor in the entire DPS. No genotype × study group interaction was seen here either.
The conversion to T2DM during the follow-up did not differ significantly among the other gene variants. In the haplotype analysis, none of the haplotypes studied were associated with an increased risk of T2DM.
Associations of UCP2 and UCP3 gene variants with waist-to-hip ratio (WHR) and serum lipid concentrations in previous studies
710, South Indian
C in haplotype CGTACC
and LDL-cholesterol conc.
Heterozygous genotype combination GTI/ATD
and LDL-cholesterol conc.
Lower HDL-cholesterol concentration
Lower HDL-cholesterol concentration
To our knowledge, this is the first study exploring effects of the gene variants rs653529, rs15763, rs1726745, rs3781907 and rs11235972 on several metabolic traits. Interestingly, subjects with rs3781907-G allele experienced a higher risk of T2DM and dyslipidemia compared with subjects homozygous for the common allele. The conversion to T2DM and serum levels of total cholesterol, LDL-cholesterol and total cholesterol-to-HDL-cholesterol ratio were modified by the dosage of rs3781907-G allele. The UCP3 promoter variant rs1800849, which is located in the same haploblock and is in LD with rs3781907, has been previously shown to be associated with an increased  or decreased  risk of T2DM, increased skeletal muscle UCP3 mRNA expression , higher total, LDL-  and HDL-cholesterol concentrations , higher  or lower BMI [30–32], higher WHR [27, 43] and higher fat mass and lean mass . In this study rs1800849 was associated with higher total cholesterol and LDL-cholesterol concentration at baseline, both as alleles and also as a member of the haploblock 3, in line with findings from earlier studies . Interestingly, all the haploblock 3 variants were associated with total and LDL-cholesterol at the baseline, although the most consistent association with various serum lipoprotein and lipid concentrations at baseline and longitudinally was seen for rs3781907 that was also a risk factor for conversion to T2DM. FDR was low for these associations, which further provides support for our findings. However, as no previous studies with this variant exist, a confirmation of the present results is needed in other populations.
Although none of the gene variants were associated with weight or BMI, variants in the haploblock 2 associated with several indices of abdominal obesity at baseline (rs659366, rs653529, rs15763, rs1726745) and longitudinally (rs653529, rs15763, rs1726745). Although waist circumference and BMI are strongly correlated , WC, WHR and WHtR are all independent obesity-related predictors of cardiovascular risk independent of BMI , and together with serum lipid concentrations they are simple clinical surrogate markers of excess visceral/ectopic fat . In this study the genetic variation in UCP2-UCP3 gene cluster seemed to be also associated with both serum lipids and indices of abdominal obesity as well. The single-marker associations were mostly haploblock specific, so that the markers from haploblock 2 were associated with central obesity indices, whereas the markers from the haploblock 3 were associated with serum cholesterol concentrations. The results of haplotype analyses were in line with the results of single marker analyses, but they did not reveal a haplotype that would explain the associations substantially better than the individual markers. We conclude that rs1726745 explains most of the associations (both baseline and longitudinal) seen in haploblock 2 with central obesity, and rs3781907 explains most of the associations seen in haploblock 3 with total and LDL-cholesterol concentrations. However, it is difficult to suggest whether the causative variant truly is one of the studied markers or simply a SNP that is in complete disequilibrium with them.
As for the functional UCP2 promoter variant -866 GA (rs659366), previous studies have found that it is associated with a reduced prevalence of obesity , reduced risk of coronary artery disease , reduced  or increased  risk of T2DM, lower insulin secretion [15, 53], reduced insulin sensitivity , a decreased  or increased UCP2 mRNA level in adipose tissue, higher oxidative stress and risk of coronary heart disease , decreased HDL-cholesterol , and increased serum triglyceride, total cholesterol and LDL-cholesterol levels . In our study, the subjects with the rs659366-A allele had lower WC and WHR at baseline, compared with subjects with G allele, both individually as well as a member of haploblock 2. Also the insulin secretion, measured by HOMA-IS, seemed to be decreased most in the subjects with rs659366-A allele during the 3-year follow-up, although no differences were seen at the baseline. These findings are in line with previous findings [15, 17, 53]. FDR was low for the associations with abdominal obesity indices thus supporting it, but high for the associations with HOMA-IS, which of course weakens the strength of this finding.
UCP2 has been said to act as adiposity angel and diabetes devil , whereas increased expression of UCP3 has been suggested to be associated with weight loss success . The promoter area variant alleles in UCP2 (rs659366-A) and in UCP3 (rs1800849-T) have been shown to increase gene expression, and thus these alleles might protect against obesity. In our study the rs659366-A allele were associated with lower WHR and WC at baseline, in line with findings by Esterbauer et al. . However, no association between rs1800849 and obesity was seen in this study. Neither were the promoter area variants associated with risk of T2DM. This could be due to the relatively small study population, and also the genetic 'makeup' varies from one population to another. Furthermore, as the mean BMI of the study population was 31.2 kg/m2, the 'obese character' may also have masked the effects of these genetic variants, which may explain the lack of association with obesity.
In summary, several novel findings were detected and they need to be confirmed. The subjects with the rs3781907-G allele had higher levels of serum total and LDL-cholesterol concentrations at baseline and at longitudinal follow-up, and a higher risk of T2DM, when compared with the subjects with A-allele. The subjects with rs1726745-G, rs11235972-A and rs1800849-T alleles had also higher serum total and LDL-cholesterol concentrations compared with those carrying the more common alleles. Several variants (rs659366-AA, rs653529-GG, rs15763-AA and rs1726745-GG) were associated with lower abdominal obesity indices, at baseline and longitudinally.
This work has been financially supported by grants from the Academy of Finland (no. 40758 to M.U.; 38387 and 46558 to J.T.; 73566 to S.K-K.), the EVO-fund of the Kuopio University Hospital (no. 5179 and 5198 to M.U.), the Ministry of Education of Finland, and the Finnish Diabetes Research Foundation, Yrjö Jahnsson Foundation, Juho Vainio Foundation, Sigrid Juselius Foundation and Finnish Cultural Foundation. The technical assistance of Minna Kiuttu, Tuomas Mäkinen and Päivi Turunen is acknowledged.
- Chan CB, Kashemsant N: Regulation of insulin secretion by uncoupling protein. Biochem Soc Trans. 2006, 34 (Pt 5): 802-805.View ArticlePubMedGoogle Scholar
- Arsenijevic D, Onuma H, Pecqueur C, Raimbault S, Manning BS, Miroux B, Couplan E, Alves-Guerra MC, Goubern M, Surwit R, Bouillaud F, Richard D, Collins S, Ricquier D: Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet. 2000, 26 (4): 435-439. 10.1038/82565.View ArticlePubMedGoogle Scholar
- De Souza CT, Araujo EP, Stoppiglia LF, Pauli JR, Ropelle E, Rocco SA, Marin RM, Franchini KG, Carvalheira JB, Saad MJ, Boschero AC, Carneiro EM, Velloso LA: Inhibition of UCP2 expression reverses diet-induced diabetes mellitus by effects on both insulin secretion and action. FASEB J. 2007, 21 (4): 1153-1163. 10.1096/fj.06-7148com.View ArticlePubMedGoogle Scholar
- Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng XX, Wheeler MB, Shulman GI, Chan CB, Lowell BB: Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell. 2001, 105 (6): 745-755. 10.1016/S0092-8674(01)00378-6.View ArticlePubMedGoogle Scholar
- Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud F, Seldin MF, Surwit RS, Ricquier D, Warden CH: Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet. 1997, 15 (3): 269-272. 10.1038/ng0397-269.View ArticlePubMedGoogle Scholar
- Solanes G, Vidal-Puig A, Grujic D, Flier JS, Lowell BB: The human uncoupling protein-3 gene. Genomic structure, chromosomal localization, and genetic basis for short and long form transcripts. J Biol Chem. 1997, 272 (41): 25433-25436. 10.1074/jbc.272.41.25433.View ArticlePubMedGoogle Scholar
- Saunders CL, Chiodini BD, Sham P, Lewis CM, Abkevich V, Adeyemo AA, de Andrade M, Arya R, Berenson GS, Blangero J, Boehnke M, Borecki IB, Chagnon YC, Chen W, Comuzzie AG, Deng HW, Duggirala R, Feitosa MF, Froguel P, Hanson RL, Hebebrand J, Huezo-Dias P, Kissebah AH, Li W, Luke A, Martin LJ, Nash M, Ohman M, Palmer LJ, Peltonen L, Perola M, Price RA, Redline S, Srinivasan SR, Stern MP, Stone S, Stringham H, Turner S, Wijmenga C, A Collier D: Meta-Analysis of Genome-wide Linkage Studies in BMI and Obesity. Obesity (Silver Spring). 2007, 15 (9): 2263-2275. 10.1038/oby.2007.269.View ArticleGoogle Scholar
- Walder K, Norman RA, Hanson RL, Schrauwen P, Neverova M, Jenkinson CP, Easlick J, Warden CH, Pecqueur C, Raimbault S, Ricquier D, Silver MH, Shuldiner AR, Solanes G, Lowell BB, Chung WK, Leibel RL, Pratley R, Ravussin E: Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima indians. Hum Mol Genet. 1998, 7 (9): 1431-1435. 10.1093/hmg/7.9.1431.View ArticlePubMedGoogle Scholar
- Kubota T, Mori H, Tamori Y, Okazawa H, Fukuda T, Miki M, Ito C, Fleury C, Bouillaud F, Kasuga M: Molecular screening of uncoupling protein 2 gene in patients with noninsulin-dependent diabetes mellitus or obesity. J Clin Endocrinol Metab. 1998, 83 (8): 2800-2804. 10.1210/jc.83.8.2800.PubMedGoogle Scholar
- Cassell PG, Neverova M, Janmohamed S, Uwakwe N, Qureshi A, McCarthy MI, Saker PJ, Albon L, Kopelman P, Noonan K, Easlick J, Ramachandran A, Snehalatha C, Pecqueur C, Ricquier D, Warden C, Hitman GA: An uncoupling protein 2 gene variant is associated with a raised body mass index but not Type II diabetes. Diabetologia. 1999, 42 (6): 688-692. 10.1007/s001250051216.View ArticlePubMedGoogle Scholar
- Ukkola O, Tremblay A, Sun G, Chagnon YC, Bouchard C: Genetic variation at the uncoupling protein 1, 2 and 3 loci and the response to long-term overfeeding. Eur J Clin Nutr. 2001, 55 (11): 1008-1015. 10.1038/sj.ejcn.1601261.View ArticlePubMedGoogle Scholar
- Rosmond R, Bouchard C, Bjorntorp P: Lack of association between the uncoupling protein-2 Ala55Val gene polymorphism and phenotypic features of the Metabolic Syndrome. Biochim Biophys Acta. 2002, 1588 (2): 103-105.View ArticlePubMedGoogle Scholar
- Wang H, Chu WS, Lu T, Hasstedt SJ, Kern PA, Elbein SC: Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol Endocrinol Metab. 2004, 286 (1): E1-7. 10.1152/ajpendo.00231.2003.View ArticlePubMedGoogle Scholar
- Krempler F, Esterbauer H, Weitgasser R, Ebenbichler C, Patsch JR, Miller K, Xie M, Linnemayr V, Oberkofler H, Patsch W: A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans. Diabetes. 2002, 51 (11): 3331-3335. 10.2337/diabetes.51.11.3331.View ArticlePubMedGoogle Scholar
- Sesti G, Cardellini M, Marini MA, Frontoni S, D'Adamo M, Del Guerra S, Lauro D, De Nicolais P, Sbraccia P, Del Prato S, Gambardella S, Federici M, Marchetti P, Lauro R: A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. Diabetes. 2003, 52 (5): 1280-1283. 10.2337/diabetes.52.5.1280.View ArticlePubMedGoogle Scholar
- Le Fur S, Le Stunff C, Dos Santos C, Bougneres P: The common -866 g/a polymorphism in the promoter of uncoupling protein 2 is associated with increased carbohydrate and decreased lipid oxidation in juvenile obesity. Diabetes. 2004, 53 (1): 235-239. 10.2337/diabetes.53.1.235.View ArticlePubMedGoogle Scholar
- Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F, Ladurner G, Hell E, Strosberg AD, Patsch JR, Krempler F, Patsch W: A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet. 2001, 28 (2): 178-183. 10.1038/88911.View ArticlePubMedGoogle Scholar
- Dhamrait SS, Stephens JW, Cooper JA, Acharya J, Mani AR, Moore K, Miller GJ, Humphries SE, Hurel SJ, Montgomery HE: Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur Heart J. 2004, 25 (6): 468-475. 10.1016/j.ehj.2004.01.007.View ArticlePubMedGoogle Scholar
- Dalgaard LT, Pedersen O: Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and Type II diabetes. Diabetologia. 2001, 44 (8): 946-965. 10.1007/s001250100596.View ArticlePubMedGoogle Scholar
- Kovacs P, Ma L, Hanson RL, Franks P, Stumvoll M, Bogardus C, Baier LJ: Genetic variation in UCP2 (uncoupling protein-2) is associated with energy metabolism in Pima Indians. Diabetologia. 2005, 48 (11): 2292-2295. 10.1007/s00125-005-1934-9.View ArticlePubMedGoogle Scholar
- Oberkofler H, Iglseder B, Klein K, Unger J, Haltmayer M, Krempler F, Paulweber B, Patsch W: Associations of the UCP2 gene locus with asymptomatic carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2005, 25 (3): 604-610. 10.1161/01.ATV.0000153141.42033.22.View ArticlePubMedGoogle Scholar
- Argiles JM, Busquets S, Lopez-Soriano FJ: The role of uncoupling proteins in pathophysiological states. Biochem Biophys Res Commun. 2002, 293 (4): 1145-1152. 10.1016/S0006-291X(02)00355-8.View ArticlePubMedGoogle Scholar
- Schrauwen P, Hesselink M: UCP2 and UCP3 in muscle controlling body metabolism. J Exp Biol. 2002, 205 (Pt 15): 2275-2285.PubMedGoogle Scholar
- Nabben M, Hoeks J: Mitochondrial uncoupling protein 3 and its role in cardiac- and skeletal muscle metabolism. Physiol Behav. 2008, 94 (2): 259-269. 10.1016/j.physbeh.2007.11.039.View ArticlePubMedGoogle Scholar
- Schrauwen P, Xia J, Walder K, Snitker S, Ravussin E: A novel polymorphism in the proximal UCP3 promoter region: effect on skeletal muscle UCP3 mRNA expression and obesity in male non-diabetic Pima Indians. Int J Obes Relat Metab Disord. 1999, 23 (12): 1242-1245. 10.1038/sj.ijo.0801057.View ArticlePubMedGoogle Scholar
- Schrauwen P, Xia J, Bogardus C, Pratley RE, Ravussin E: Skeletal muscle uncoupling protein 3 expression is a determinant of energy expenditure in Pima Indians. Diabetes. 1999, 48 (1): 146-149. 10.2337/diabetes.48.1.146.View ArticlePubMedGoogle Scholar
- Herrmann SM, Wang JG, Staessen JA, Kertmen E, Schmidt-Petersen K, Zidek W, Paul M, Brand E: Uncoupling protein 1 and 3 polymorphisms are associated with waist-to-hip ratio. J Mol Med. 2003, 81 (5): 327-332.PubMedGoogle Scholar
- Meirhaeghe A, Amouyel P, Helbecque N, Cottel D, Otabe S, Froguel P, Vasseur F: An uncoupling protein 3 gene polymorphism associated with a lower risk of developing Type II diabetes and with atherogenic lipid profile in a French cohort. Diabetologia. 2000, 43 (11): 1424-1428. 10.1007/s001250051549.View ArticlePubMedGoogle Scholar
- Otabe S, Clement K, Dina C, Pelloux V, Guy-Grand B, Froguel P, Vasseur F: A genetic variation in the 5' flanking region of the UCP3 gene is associated with body mass index in humans in interaction with physical activity. Diabetologia. 2000, 43 (2): 245-249. 10.1007/s001250050037.View ArticlePubMedGoogle Scholar
- Liu YJ, Liu PY, Long J, Lu Y, Elze L, Recker RR, Deng HW: Linkage and association analyses of the UCP3 gene with obesity phenotypes in Caucasian families. Physiol Genomics. 2005, 22 (2): 197-203. 10.1152/physiolgenomics.00031.2005.View ArticlePubMedGoogle Scholar
- Halsall DJ, Luan J, Saker P, Huxtable S, Farooqi IS, Keogh J, Wareham NJ, O'Rahilly S: Uncoupling protein 3 genetic variants in human obesity: the c-55t promoter polymorphism is negatively correlated with body mass index in a UK Caucasian population. Int J Obes Relat Metab Disord. 2001, 25 (4): 472-477. 10.1038/sj.ijo.0801584.View ArticlePubMedGoogle Scholar
- Hamada T, Kotani K, Fujiwara S, Sano Y, Domichi M, Tsuzaki K, Sakane N: The common -55 C/T polymorphism in the promoter region of the uncoupling protein 3 gene reduces prevalence of obesity and elevates serum high-density lipoprotein cholesterol levels in the general Japanese population. Metabolism. 2008, 57 (3): 410-415. 10.1016/j.metabol.2007.10.019.View ArticlePubMedGoogle Scholar
- van Abeelen AF, de Krom M, Hendriks J, Grobbee DE, Adan RA, Schouw van der YT: Variations in the uncoupling protein-3 gene are associated with specific obesity phenotypes. Eur J Endocrinol. 2008, 158 (5): 669-676. 10.1530/EJE-07-0834.View ArticlePubMedGoogle Scholar
- Cha MH, Shin HD, Kim KS, Lee BH, Yoon Y: The effects of uncoupling protein 3 haplotypes on obesity phenotypes and very low-energy diet-induced changes among overweight Korean female subjects. Metabolism. 2006, 55 (5): 578-586. 10.1016/j.metabol.2005.11.012.View ArticlePubMedGoogle Scholar
- Dalgaard LT, Sorensen TI, Drivsholm T, Borch-Johnsen K, Andersen T, Hansen T, Pedersen O: A prevalent polymorphism in the promoter of the UCP3 gene and its relationship to body mass index and long term body weight change in the Danish population. J Clin Endocrinol Metab. 2001, 86 (3): 1398-1402. 10.1210/jc.86.3.1398.PubMedGoogle Scholar
- de Luis DA, Aller R, Izaola O, Gonzalez Sagrado M, Conde R, Perez Castrillon JL: Lack of association of -55CT polymorphism of UCP3 gene with fat distribution in obese patients. Ann Nutr Metab. 2007, 51 (4): 374-378. 10.1159/000107685.View ArticlePubMedGoogle Scholar
- Uusitupa M, Louheranta A, Lindström J, Valle T, Sundvall J, Eriksson J, Tuomilehto J: The Finnish Diabetes Prevention Study. Br J Nutr. 2000, 83 (Suppl 1): S137-42.PubMedGoogle Scholar
- Eriksson J, Lindström J, Valle T, Aunola S, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljanen T, Uusitupa M, Tuomilehto J: Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia. 1999, 42 (7): 793-801. 10.1007/s001250051229.View ArticlePubMedGoogle Scholar
- Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001, 344 (18): 1343-1350. 10.1056/NEJM200105033441801.View ArticlePubMedGoogle Scholar
- Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R: Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia. 2000, 43 (12): 1507-1511. 10.1007/s001250051561.View ArticlePubMedGoogle Scholar
- Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18 (6): 499-502.PubMedGoogle Scholar
- de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D: Efficiency and power in genetic association studies. Nat Genet. 2005, 37 (11): 1217-1223. 10.1038/ng1669.View ArticlePubMedGoogle Scholar
- Cassell PG, Saker PJ, Huxtable SJ, Kousta E, Jackson AE, Hattersley AT, Frayling TM, Walker M, Kopelman PG, Ramachandran A, Snehelatha C, Hitman GA, McCarthy MI: Evidence that single nucleotide polymorphism in the uncoupling protein 3 (UCP3) gene influences fat distribution in women of European and Asian origin. Diabetologia. 2000, 43 (12): 1558-1564. 10.1007/s001250051569.View ArticlePubMedGoogle Scholar
- Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21 (2): 263-265. 10.1093/bioinformatics/bth457.View ArticlePubMedGoogle Scholar
- Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL: A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet. 2004, 68 (Pt 2): 165-177. 10.1046/j.1529-8817.2003.00085.x.View ArticlePubMedGoogle Scholar
- Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003, 100 (16): 9440-9445. 10.1073/pnas.1530509100.View ArticlePubMedPubMed CentralGoogle Scholar
- Gable DR, Stephens JW, Cooper JA, Miller GJ, Humphries SE: Variation in the UCP2-UCP3 gene cluster predicts the development of type 2 diabetes in healthy middle-aged men. Diabetes. 2006, 55 (5): 1504-1511. 10.2337/db05-1645.View ArticlePubMedGoogle Scholar
- Damcott CM, Feingold E, Moffett SP, Barmada MM, Marshall JA, Hamman RF, Ferrell RE: Genetic variation in uncoupling protein 3 is associated with dietary intake and body composition in females. Metabolism. 2004, 53 (4): 458-464. 10.1016/j.metabol.2003.11.019.View ArticlePubMedGoogle Scholar
- Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodes-Cabau J, Bertrand OF, Poirier P: Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008, 28 (6): 1039-1049. 10.1161/ATVBAHA.107.159228.View ArticlePubMedGoogle Scholar
- Lee CM, Huxley RR, Wildman RP, Woodward M: Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol. 2008, 61 (7): 646-653. 10.1016/j.jclinepi.2007.08.012.View ArticlePubMedGoogle Scholar
- Cheurfa N, Dubois-Laforgue D, Ferrarezi DA, Reis AF, Brenner GM, Bouche C, Le Feuvre C, Fumeron F, Timsit J, Marre M, Velho G: The common -866G>A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men. Diabetes. 2008, 57 (4): 1063-1068. 10.2337/db07-1292.View ArticlePubMedGoogle Scholar
- Bulotta A, Ludovico O, Coco A, Di Paola R, Quattrone A, Carella M, Pellegrini F, Prudente S, Trischitta V: The common -866G/A polymorphism in the promoter region of the UCP-2 gene is associated with reduced risk of type 2 diabetes in Caucasians from Italy. J Clin Endocrinol Metab. 2005, 90 (2): 1176-1180. 10.1210/jc.2004-1072.View ArticlePubMedGoogle Scholar
- Sasahara M, Nishi M, Kawashima H, Ueda K, Sakagashira S, Furuta H, Matsumoto E, Hanabusa T, Sasaki H, Nanjo K: Uncoupling protein 2 promoter polymorphism -866G/A affects its expression in beta-cells and modulates clinical profiles of Japanese type 2 diabetic patients. Diabetes. 2004, 53 (2): 482-485. 10.2337/diabetes.53.2.482.View ArticlePubMedGoogle Scholar
- D'Adamo M, Perego L, Cardellini M, Marini MA, Frontoni S, Andreozzi F, Sciacqua A, Lauro D, Sbraccia P, Federici M, Paganelli M, Pontiroli AE, Lauro R, Perticone F, Folli F, Sesti G: The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes. Diabetes. 2004, 53 (7): 1905-1910. 10.2337/diabetes.53.7.1905.View ArticlePubMedGoogle Scholar
- Cha MH, Kim IC, Kim KS, Kang BK, Choi SM, Yoon Y: Association of UCP2 and UCP3 gene polymorphisms with serum high-density lipoprotein cholesterol among Korean women. Metabolism. 2007, 56 (6): 806-813. 10.1016/j.metabol.2007.01.023.View ArticlePubMedGoogle Scholar
- Reis AF, Dubois-Laforgue D, Bellanne-Chantelot C, Timsit J, Velho G: A polymorphism in the promoter of UCP2 gene modulates lipid levels in patients with type 2 diabetes. Mol Genet Metab. 2004, 82 (4): 339-344. 10.1016/j.ymgme.2004.06.008.View ArticlePubMedGoogle Scholar
- O'Rahilly S: Uncoupling protein 2: Adiposity angel and diabetes devil?. Nat Med. 2001, 7 (7): 770-772. 10.1038/89877.View ArticlePubMedGoogle Scholar
- Bezaire V, Seifert EL, Harper ME: Uncoupling protein-3: clues in an ongoing mitochondrial mystery. FASEB J. 2007, 21 (2): 312-324. 10.1096/fj.06-6966rev.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2350/10/94/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.